Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects

Sleep

Volumn 37, Issue 10, 2014, Pages 1609-1619

  Ma, Junshui ^a   Svetnik, Vladimir ^a   Snyder, Ellen ^a   Lines, Christopher ^a   Roth, Thomas ^b   Herring, W Joseph ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Gaboxadol; Orexin; Polysomnography; QEEG; Suvorexant; Trazodone; Zolpidem

Indexed keywords

GABOXADOL; PLACEBO; SUVOREXANT; TRAZODONE; ZOLPIDEM; AZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; OREXIN RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; EVENING DOSAGE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); POWER SPECTRAL DENSITY; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SPECTROMETRY; STATISTICAL ANALYSIS; CLINICAL TRIAL; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; MIDDLE AGED; NORMAL HUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

ADULT; AGED; AZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OREXIN RECEPTOR ANTAGONISTS; POLYSOMNOGRAPHY; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZOLES; YOUNG ADULT;

EID: 84907923574     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.4068     Document Type: Article

References (46)

1. National Institutes of Health. NIH statement regarding the treatment of insomnia. state of the science conference statement: manifestations and management of chronic insomnia in adults. Sleep 2005;28:1049-57.
2. Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics 2012;9:728-38.
3. Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol 2009;11:349-57.
4. Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: a review. Expert Opin Pharmacother 2012;13:1707-17.
5. Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88.
6. Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci 2010;1200:149-61.
7. Taheri S, Sunter D, Dakin C, et al. Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. Neurosci Lett 2000;279:109-12.
8. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23:3555-60.
9. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5.
10. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl- 1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-32.
11. Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61.
12. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67.
13. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012;79:2265-74.
14. Connor K, Budd K, Snavely D. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the first of two 3-month pivotal phase 3 trials. J Sleep Res 2012;21:97.
15. Ivgy-May N, Leibensperger H, Froman S. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the second of two 3-month pivotal phase 3 trials. J Sleep Res 2012;21:351-2.
16. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant, an orexin receptor antagonist, during 1-year treatment of insomnia followed by abrupt discontinuation of treatment: a randomized, doubleblind, placebo-controlled clinical trial. Lancet Neurology 2014;13:461-71.
17. Iber C, Ancoli-Israel S, Chesson AL Jr, Quan SF. The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications. Westchester, IL, American Academy of Sleep Medicine, 2007.
18. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington DC, Public Health Service, US Government Printing Office, 1968.
19. Van Bemmel AL, Beersma DG, Van den Hoofdakker RH. Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. J Affect Disord 1995;35:11-9.
20. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33.
21. Lundahl J, Deacon S, Maurice D, Staner L. EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia. J Psychopharmacol 2012;26:1081-7.
22. Walsh JK, Deacon S, Dijk DJ, Lundahl J. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 2007;30:593-602.
23. Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097-104.
24. Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012; 91:975-85.
25. Lankford DA, Corser BC, Zheng YP, et al. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies. Sleep 2008;31:1359-70.
26. Roth T, Lines C, Vandormael K, Ceesay P, Anderson D, Snavely D. Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies. J Clin Sleep Med 2010;6:30-9.
27. Svetnik V, Ferri R, Ray S, et al. Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem. Sleep 2010;33:1562-70.
28. Ma J, Dijk DJ, Svetnik V, et al. EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women. J Clin Sleep Med 2011;7:493-501A.
29. Welch PD. The use of fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans Audio Electroacoustics 1967;15:70-3.
30. Borbely AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985;4:189-94.
31. Dijk DJ, Hayes B, Czeisler CA. Dynamics of electroencephalographic sleep spindles and slow wave activity in men: effect of sleep deprivation. Brain Res 1993;626:190-9.
32. Pinheiro J, Bates D. Mixed-effects models in S and S-PLUS. New York, Springer-Verlag, 2000.
33. Carrier J, Land S, Buysse DJ, Kupfer DJ, Monk TH. The effects of age and gender on sleep EEG power spectral density in the middle years of life (ages 20-60 years old). Psychophysiology 2001;38:232-42.
34. de Boor C. A practical guide to splines. New York, Springer-Verlag, 1978:113-4.
35. Ma J, Svetnik V. A natural approach for addressing multiplicity involving neuroscience functional data. In JSM Proceedings, Biopharmaceutical Section. Alexandria, VA, American Statistical Association, 2011.
36. Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother 2012; 13:879-93.
37. Bon OL. Low-dose trazodone effective in insomnia. Pharmacopsychiatry 2005; 38:226.
38. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res 2011;20:552-8.
39. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006;112:612-29.
40. Brunner DP, Dijk DJ, Munch M, Borbely AA. Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) 1991;104:1-5.
41. Riemann D, Spiegelhalder K, Espie C, et al. Chronic insomnia: clinical and research challenges - an agenda. Pharmacopsychiatry 2011;44:1-14.
42. Spiegelhalder K, Regen W, Feige B, et al. Increased EEG sigma and beta power during NREM sleep in primary insomnia. Biol Psychol 2012;91:329-33.
43. Buysse DJ, Germain A, Hall ML, et al. EEG spectral analysis in primary insomnia: NREM period effects and sex differences. Sleep 2008;31:1673-82.
44. Svetnik V, Snyder E, Ivgy-May N, Ma J, Tao P, Herring W. Comparison of EEG power spectra between patients with primary insomnia and good sleeper controls, accounting for the effects of age, gender, and sleep period, using a large compilation of PSG recordings from three clinical trials. Sleep Medicine 2013;14S:e278.
45. Roehrs T, Roth T. Drug-related sleep stage changes: functional significance and clinical relevance. Sleep Med Clin 2010;5:559-70.
46. Fox SV, Gotter AL, Tye SJ, et al. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 2013;38:2401-8.